Important Drug Warning from Amylin

An important FDA-approved Drug Alert for Bydureon affecting Family/General Practice, Internal Medicine, Endocrinology, Nurse Practitioners, and Physician Assistants was published on August 1, 2012. This PDR® Drug Alert was delivered electronically to all Arkansas Medical Society members within these specialties who are registered with PDR® Network.

To ensure that your members immediately receive electronic PDR® Drug Alerts, please encourage them to register at http://www.arkmed.pdr.net.

ArkMed members not registered to receive PDR Drug Alerts may view this information on PDR.net®.

PDR Drug Alerts offer immediate, electronic delivery of FDA-approved, specialty-specific Drug Alerts, and safety information for ArkMed members, and are aggregated on PDR.net for convenient review. As an added benefit, your members may also earn continuing medical education (CME) credit for Drug Alerts and FDA-approved product labeling. More information is available on PDR.net.

Included below is an email template which can be personalized and distributed to your members to inform them of the recent PDR Drug Alert, and how to register for future Alerts and related CME.

Please let me know if you have any questions or if I may assist in any way. As always, thank you for your continued support and commitment to patient safety.

Sincerely,

Jason Willett
Director of Medical Communications & Partner Relations
PDR Network
415-644-3926
jason.willett@pdr.net

Partner Alert Notification Template
From: Arkansas Medical Society
To: {ArkMed_MEMBER_EMAIL}
Subject: Important Drug Warning from Amylin

{INSERT_ArkMed_LOGO}

Dear {ArkMed_MEMBER_NAME}:

An important FDA-approved Drug Alert for Bydureon affecting Family/General Practice, Internal Medicine, Endocrinology, Nurse Practitioners, and Physician Assistants was published on August 1, 2012. This PDR® Drug Alert was delivered electronically to all Arkansas Medical Society members within these specialties who are registered with PDR® Network. If you have already registered to receive these Alerts, please check your email immediately for this important patient safety-related information.

If you have not yet registered to receive electronic PDR® Drug Alerts, please do so at http://www.arkmed.pdr.net. Your email or fax number will only be used to send and administer Drug and Device Alert services, FDA-approved drug labeling information, and other clinically relevant PDR services/information. If you do not register to receive PDR Drug Alerts, you will not receive them immediately by email or fax, but may view this information on PDR.net.

PDR Drug Alerts offer immediate, electronic delivery of FDA-approved, specialty-specific Drug Alerts, and safety information for ArkMed members, and are aggregated on PDR.net® for convenient review.

Register today at http://www.arkmed.pdr.net to receive up-to-date, ongoing delivery of important product safety and recall information. This valuable PDR Network service provides:

  • Free FDA-approved Drug Alerts and recalls sent electronically to you
  • CME opportunities for reviewing Drug Alerts and full FDA labels on PDR.net
  • Endorsement by ArkMed
  • Improved patient safety which may help reduce physician liability
  • Elimination of the delays and inefficiencies of traditional paper Alerts
  • Privacy oversight from the governing not-for-profit Board, the iHealth Alliance

Thank you for your membership and commitment to patient safety.

Sincerely,
{ArkMed_SPOKESPERSON_SIGNATURE}
{ArkMed_SPOKESPERSON}
{TITLE}
Arkansas Medical Society